Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Padcev“
Suchtreffer
Begriffe & Kennungen
Padcev · 4.8 · A total of 159 patients were tested for immunogenicity against enfortumab vedotin following enfortumab vedotin
Eintrag öffnenPadcev · 4.8 · A total of 490 patients were tested for immunogenicity against enfortumab vedotin following enfortumab vedotin
Eintrag öffnenPadcev · 4.8 · A total of 697 patients were tested for immunogenicity to enfortumab vedotin 1.25 mg/kg as monotherapy; 16 pat
Eintrag öffnenPadcev · 4.8 · Adverse reactions leading to dose interruption occurred in 62% of patients; the most common adverse reactions
Eintrag öffnenPadcev · 4.8 · Adverse reactions leading to dose interruption of enfortumab vedotin occurred in 59% of patients. The most com
Eintrag öffnenPadcev · 4.8 · Adverse reactions leading to dose reduction of enfortumab vedotin occurred in 31% of patients. The most common
Eintrag öffnenPadcev · 4.8 · Adverse reactions observed during clinical studies of enfortumab vedotin as monotherapy or in combination with
Eintrag öffnenPadcev · 4.8 · Due to the limited number of patients with antibodies against Padcev, no conclusions can be drawn concerning a
Eintrag öffnenPadcev · 4.8 · Enfortumab vedotin in combination with pembrolizumab
Eintrag öffnenPadcev · 4.8 · Enfortumab vedotin in combination with pembrolizumab has been studied in 359 patients <65 years and 775 patien
Eintrag öffnenPadcev · 4.8 · Frequency Monotherapy In combination with pembrolizumab Infections and infestations Very common Urinary tract
Eintrag öffnenPadcev · 4.8 · Hyperglycaemia
Eintrag öffnenPadcev · 4.8 · Immunogenicity
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, 30% of patients experienced dry eye during treatment
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, hyperglycaemia (blood glucose >13.9 mmol/L) occurred
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, peripheral neuropathy occurred in 53% (422) of the 7
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, pneumonitis/ILD occurred in 3.3% (26) of the 793 pat
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, skin reactions occurred in 57% (452) of the 793 pati
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin in combination with pembrolizumab, pneumonitis/ILD occurred in 8.8%
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin in combination with pembrolizumab, skin reactions occurred in 67% (7
Eintrag öffnen